Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Insulin lispro is a modified form of fast-acting insulin used to control hyperglycemia in diabetes mellitus. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism.
- Mechanism
- Curator reviewed
Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and m-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.
- Primary indication
- Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.Curator reviewed · 7 structured indications
- Formula / weight
- C257H387N65O76S6 · 5808.0 Da
- First approval
- Canada, 1997 · United States, 1996 · European Union, 2016
- Also known as
- Insulin lispro (genetical recombination) · Insulin lispro (rDNA origin) · Insulin lispro protamine · Insulin lispro protamine recombinant · Insulin lispro recombinant
- Code names
- LY-275585 · LY900014 · SAR-342434
- Brand names
- Admelog
- Humalog
- Humalog Mix
- Humalog kwikpen
- Insulin Lispro Sanofi
- Lyumjev
- Lyumjev Kwikpen
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Insulin lispro, and which of those have an active Phase 3 trial?